Merck : MRK

All Merck Articles

1083 Articles

Lee Jackson | Aug 1, 2014 at 10:25 AM EDT

UBS Adds New Stocks to Buy to Its Equity Focus List

With interest rates still at historic lows, the stock market is ultimately the only destination for investor capital, and dividend-paying…

Paul Ausick | Jul 29, 2014 at 7:50 AM EDT

Drugmakers Merck, Pfizer Eke Out Profit Hikes

Drug giants Merck and Pfizer reported better-than-expected second-quarter 2014 results before markets opened Tuesday morning.

Jon C. Ogg | Jul 25, 2014 at 10:30 AM EDT

Key Short Interest Changes in Defensive High-Yield Dividend Stocks

The short interest data for the July 15 settlement date is out and we have compared the defensive dividend stocks,…

Lee Jackson | Jul 12, 2014 at 9:26 AM EDT

Key Companies With Insider Selling This Week

Wikimedia CommonsIn a week that saw more than its share of volatility some top insiders decided it was time to…

Jon C. Ogg | Jul 11, 2014 at 7:40 AM EDT

Short Sellers Get Aggressive in Defensive High-Yield Dividend Stocks

The short interest data for the June 30 settlement date is out, and there were selectively an increasing number of…

Jon C. Ogg | Jul 1, 2014 at 7:55 AM EDT

The Five Best Performing DJIA Stocks of 2014

The second quarter of 2014 has come and gone, which means that we are now already half way through 2014.…

Jon C. Ogg | Jun 25, 2014 at 10:05 AM EDT

Short Interest Screams Higher in Defensive High-Yield Stocks

The short interest data for the first two weeks of June show that short interest was higher in almost all…

Jon C. Ogg | Jun 11, 2014 at 11:45 AM EDT

Short Sellers Get Selective in High-Yield Defensive Dividend Stocks

ThinkstockThe short interest data for the final two weeks of May have been released, and the results are somewhat surprising…

Jon C. Ogg | Jun 10, 2014 at 8:20 AM EDT

After Idenix: The Next Four Biotech Buyout Candidates

Here are the four top biotech names we found that all have hepatitis C drugs in their current pipelines at…

Jon C. Ogg | Jun 9, 2014 at 12:45 PM EDT

The Top Seven DJIA Stocks of 2014 Expected to Keep Rising

24/7 Wall St. wanted to look at the leaders and laggards in the Dow Jones Industrial Average. It turns out…

Paul Ausick | May 29, 2014 at 4:01 PM EDT

The 4 Stocks That Dominated the Market

thinkstockMay 29, 2014: Markets opened higher on Thursday following reports that U.S. GDP contracted by 1% in the first quarter…

Jon C. Ogg | May 27, 2014 at 1:35 PM EDT

Pfizer’s Real Issue: Identity Crisis Against Peers

Pfizer looks like it is out of the bid now for AstraZeneca. What looks increasingly obvious for a lackluster performance…

Paul Ausick | May 8, 2014 at 4:01 PM EDT

The 4 Stocks That Mixed Up the Market

thinkstockMay 8, 2014: Markets opened lower on Thursday and posted solid gains on a good report on new claims for…

Jon C. Ogg | May 8, 2014 at 8:30 AM EDT

Top Analyst Upgrades and Downgrades: Chevron, Exxon, Merck, Tesla, Disney, Yelp and More

These are the top Wall Street analyst upgrades, downgrades and initiations for Thursday, May 8, 2014. They include Chevron, Exxon,…

Paul Ausick | May 6, 2014 at 4:01 PM EDT

The 4 Stocks That Tanked the Market

thinkstockMay 6, 2014: Markets opened lower on Monday and sank slowly and surely for the rest of the day. The…

1 … 47 48 49 50 51 … 73

Merck : MRK

All Merck Articles

UBS Adds New Stocks to Buy to Its Equity Focus List

Drugmakers Merck, Pfizer Eke Out Profit Hikes

Key Short Interest Changes in Defensive High-Yield Dividend Stocks

Key Companies With Insider Selling This Week

Short Sellers Get Aggressive in Defensive High-Yield Dividend Stocks

The Five Best Performing DJIA Stocks of 2014

Short Interest Screams Higher in Defensive High-Yield Stocks

Short Sellers Get Selective in High-Yield Defensive Dividend Stocks

After Idenix: The Next Four Biotech Buyout Candidates

The Top Seven DJIA Stocks of 2014 Expected to Keep Rising

The 4 Stocks That Dominated the Market

Pfizer’s Real Issue: Identity Crisis Against Peers

The 4 Stocks That Mixed Up the Market

Top Analyst Upgrades and Downgrades: Chevron, Exxon, Merck, Tesla, Disney, Yelp and More

The 4 Stocks That Tanked the Market

Want $1,500 a Month in Rent Without a Single 2 a.m. Phone Call? These 3 ETFs Pay You Like a Landlord

Why a $50,000 401(k) Loan at 50 Could Quietly Cost You $100,000 by Retirement

Inflation Subtly Stole 20% of Your Savings Since 2020. These 3 ETFs Hit Back

Why a $50,000 401(k) Loan at 50 Could Quietly Cost You $100,000 by Retirement

Her Husband Handled the Medicare Paperwork. After He Died, Her Premium Doubled Overnight.

Want $1,500 a Month in Rent Without a Single 2 a.m. Phone Call? These 3 ETFs Pay You Like a Landlord

Why a $50,000 401(k) Loan at 50 Could Quietly Cost You $100,000 by Retirement

Merck : MRK

All Merck Articles

UBS Adds New Stocks to Buy to Its Equity Focus List

Drugmakers Merck, Pfizer Eke Out Profit Hikes

Key Short Interest Changes in Defensive High-Yield Dividend Stocks

Key Companies With Insider Selling This Week

Short Sellers Get Aggressive in Defensive High-Yield Dividend Stocks

The Five Best Performing DJIA Stocks of 2014

Short Interest Screams Higher in Defensive High-Yield Stocks

Short Sellers Get Selective in High-Yield Defensive Dividend Stocks

After Idenix: The Next Four Biotech Buyout Candidates

The Top Seven DJIA Stocks of 2014 Expected to Keep Rising

The 4 Stocks That Dominated the Market

Pfizer’s Real Issue: Identity Crisis Against Peers

The 4 Stocks That Mixed Up the Market

Top Analyst Upgrades and Downgrades: Chevron, Exxon, Merck, Tesla, Disney, Yelp and More

The 4 Stocks That Tanked the Market

Want $1,500 a Month in Rent Without a Single 2 a.m. Phone Call? These 3 ETFs Pay You Like a Landlord

Why a $50,000 401(k) Loan at 50 Could Quietly Cost You $100,000 by Retirement

Inflation Subtly Stole 20% of Your Savings Since 2020. These 3 ETFs Hit Back

Featured Reads

Why a $50,000 401(k) Loan at 50 Could Quietly Cost You $100,000 by Retirement

Her Husband Handled the Medicare Paperwork. After He Died, Her Premium Doubled Overnight.